Bio-Gene Technology (ASX:BGT) Depreciation, Depletion and Amortization: A$0.05 Mil (TTM As of Dec. 2025)


What is Bio-Gene Technology Depreciation, Depletion and Amortization?

Bio-Gene Technology ASX:BGT Depreciation, Depletion and Amortization is A$0.05 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's depreciation, depletion and amortization for the six months ended in Dec. 2025 was A$0.02 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.05 Mil.


Bio-Gene Technology  (ASX:BGT) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Bio-Gene Technology Depreciation, Depletion and Amortization Related Terms


Bio-Gene Technology Depreciation, Depletion and Amortization Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Depreciation, Depletion and Amortization Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial 0.05 0.04 0.05 0.04 0.04

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.03 0.02

Bio-Gene Technology Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.05 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Depreciation, Depletion and Amortization of A$0.05 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Depreciation, Depletion and Amortization of A$0.05 Mil as of Dec. 2025. Cash Flow for Depreciation and Amortization is the change in accumulated depreciation between the current period and the past period. View historical data for Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Depreciation, Depletion and Amortization too high?
Bio-Gene Technology's current Depreciation, Depletion and Amortization is A$0.05 Mil.
How does Bio-Gene Technology's Depreciation, Depletion and Amortization compare to VRTX and REGN?
Bio-Gene Technology's Depreciation, Depletion and Amortization of A$0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Depreciation, Depletion and Amortization for a Biotechnology company?
A good Depreciation, Depletion and Amortization depends on the Biotechnology industry context. However, Depreciation, Depletion and Amortization should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Depreciation, Depletion and Amortization mean?
A high Depreciation, Depletion and Amortization can signal that a stock is expensive relative to its fundamentals. Cash Flow for Depreciation and Amortization is the change in accumulated depreciation between the current period and the past period. View historical data for Bio-Gene Technology and its competitors. Bio-Gene Technology's current Depreciation, Depletion and Amortization is A$0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Depreciation, Depletion and Amortization of A$0.05 Mil. The current Depreciation, Depletion and Amortization is A$0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Depreciation, Depletion and Amortization calculated?
Depreciation, Depletion and Amortization is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Depreciation, Depletion and Amortization is A$0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.